Abstract
Summary
The Liver Disease Partnering 2007-2012 report provides understanding and
access to the liver disease partnering deals and agreements entered into by
the worlds leading healthcare companies.
- Trends in liver disease partnering deals
- Top liver disease deals by value
- Deals listed by company A-Z, industry sector, stage of development,
technology type
Description
Liver Disease Partnering 2007-2012 provides understanding and access
to the liver disease partnering deals and agreements entered into by the
worlds leading healthcare companies.
The report provides an analysis of liver disease partnering deals. The
majority of deals are discovery or development stage whereby the
licensee obtains a right or an option right to license the licensors liver
disease technology. These deals tend to be multicomponent, starting with
collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals
terms provides critical insight into the negotiation process in terms of what
you can expect to achieve during the negotiation of terms. Whilst many smaller
companies will be seeking details of the payments clauses, the devil is in the
detail in terms of how payments are triggered - contract documents provide
this insight where press releases do not.
This data driven report contains over 50 links to online copies of actual
liver disease deals and contract documents as submitted to the Securities
Exchange Commission by companies and their partners, where available. Contract
documents provide the answers to numerous questions about a prospective
partner's flexibility on a wide range of important issues, many of which will
have a significant impact on each party's ability to derive value from the
deal.
The initial chapters of this report provide an orientation of liver disease
partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an
overview of the trends in liver disease partnering since 2007, including a
summary of deals by industry sector, stage of development, deal type, and
technology type. Numerous tables provide outline financial trends.
Chapter 3 provides an overview of the leading liver disease deals since 2007.
Deals are listed by headline value, signed by bigpharma, most active
bigpharma. Where the deal has an agreement contract published at the SEC a
link provides online access to the contract.
Chapter 4 provides a comprehensive directory of liver disease partnering deals
signed and announced since 2007. The chapter is organized by company A-Z,
stage of development at signing, deal type (collaborative R&D,
co-promotion, licensing etc), and technology type. Each deal title
links via Weblink to an online version of the deal record, and where available
the contract document, providing easy access to each contract document on
demand.
In conclusion, this report provides everything a prospective dealmaker needs
to know about partnering in the research, development and commercialization of
liver disease technologies and products.
Report scope
Liver Disease Partnering 2007-2012 is intended to provide the reader
with an in-depth understanding and access to liver disease trends and
structure of deals entered into by leading companies worldwide.
This data driven report includes:
- Trends in liver disease dealmaking in the biopharma industry since 2007
- Access to summary headline, upfront, milestone and royalty data
- The leading liver disease deals by value since 2007
In Liver Disease Partnering 2007-2012, the available deals are listed
by:
- Headline value
- Upfront payment value
- Royalty rate value
- Company A-Z
- Industry sector
- Stage of development at signing
- Deal component type
- Technology type
Each deal title links via Weblink to an online version of the deal record and
where available, the contract document, providing easy access to each contract
document on demand.
Benefits
Liver Disease Partnering 2007-2012 provides the reader with the
following key benefits:
- In-depth understanding of liver disease deal trends since 2007
- Access to summary headline, upfront, milestone and royalty data
- Comprehensive access to over 50 actual liver disease deals entered into by
the world's biopharma companies since 2007
- Insight into key deal terms included in contracts, where disclosed
- Understand the key deal terms companies have agreed in deals
- Undertake due diligence to assess suitability of your proposed deal terms
for partner companies
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in liver disease partnering
- 2.1. Introduction
- 2.2. Liver disease partnering over the years
- 2.3. Bigpharma liver disease dealmaking activity
- 2.4. Liver disease partnering by deal type
- 2.5. Liver disease partnering industry sector
- 2.6. Liver disease partnering by stage of development
- 2.7. Liver disease partnering by technology type
- 2.8. Disclosed financial deal terms for liver disease partnering
- 2.8.1 Liver disease headline values
- 2.8.2 Liver disease upfront payments
- 2.8.3 Liver disease milestone payments
- 2.8.4 Liver disease royalty rates
Chapter 3 - Leading liver disease deals
- 3.1. Introduction
- 3.2. Top liver disease deals by value
- 3.3. Top liver disease deals involving bigpharma
Chapter 4 - Dealmaking directory
- 4.1. Introduction
- 4.2. Company A-Z
- 4.3. By deal type
- Asset purchase
- Bigpharma outlicensing
- Co-development
- Collaborative R&D
- Co-market
- Contract service
- Co-promotion
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Settlement
- Spin out
- Sub-license
- Supply
- Termination
- 4.4. By industry sector
- Academic
- Bigpharma
- Biotech
- Drug delivery
- Medical device
- Diagnostic
- Generic pharma
- Government
- Non-profit
- Pharmaceutical
- Research tools
- Services
- Specialty pharma
- 4.5. By stage of development
- Discovery
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Registration
- Marketed
- 4.6. By technology type
- Analysis
- Animal models
- Assays
- Bioinformatics
- Biological compounds
- Biomarkers
- Biomaterials
- Cell culture
- Cell therapy
- Clinical testing
- Diagnostic - companion
- Devices
- Diagnostics
- Discovery tools
- DNA probes
- Drug delivery
- Enabling technology
- Epigenetics
- Equipment
- Facilities
- Gene therapy
- Genomics
- Imaging
- Industrial chemicals
- In vitro models
- Monoclonal antibodies
- Nanotechnology
- Oligonucleotide
- Peptides
- Personalised medicine
- Processes
- Proteomics
- Radio/Chemo-therapy
- Recombinant DNA
- Research services
- Research supplies
- RNA therapeutics
- Screening
- Small molecules
- Stem cells
- Vaccines
Chapter 5 - Partnering resource center
- 5.1. Online partnering
- 5.2. Partnering events
- 5.3. Further reading on dealmaking
Appendices
- Appendix 1 - Deal type definitions
- About Wildwood Ventures
- Current Partnering
- Current Agreements
- Recent titles from CurrentPartnering
- Order Form - Reports
Table of figures
- Figure 1: Liver disease partnering since 2007
- Figure 2: Bigpharma - top 50 - liver disease deals 2007 to 2011
- Figure 3: Bigpharma liver disease deal frequency - 2007 to 2011
- Figure 4: Liver disease partnering by deal type since 2007
- Figure 5:Liver disease partnering by industry sector since 2007
- Figure 6: Liver disease partnering by stage of development since 2007
- Figure 7: Liver disease partnering by technology type since 2007
- Figure 8: Liver disease deals with a headline value
- Figure 9: Liver disease deals with upfront payment values
- Figure 10: Liver disease deals with milestone payments
- Figure 11: Liver disease deals with royalty rates, %
- Figure 12: Top liver disease deals by value since 2007
- Figure 13: Top liver disease deals signed by bigpharma value since 2007
- Figure 14: Online partnering resources
- Figure 15: Forthcoming partnering events
- Figure 16: Deal type definitions
Liver Disease Partnering 2007-2012 published by Current Partnering, a division of Wildwood Ventures Limited. This report consists of 150 Pages and the price starts from US $ 995.
